<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617550</url>
  </required_header>
  <id_info>
    <org_study_id>17849</org_study_id>
    <secondary_id>2015-001444-11</secondary_id>
    <nct_id>NCT02617550</nct_id>
  </id_info>
  <brief_title>Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients</brief_title>
  <acronym>VENICE</acronym>
  <official_title>Evaluation of the Effect of 0.4 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 2.5 mg, 5 mg and 10 mg Vericiguat (BAY 1021189) Each Given Over 14 ± 3 Days on Safety, Tolerability and Blood Pressure in a Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study in Stable Coronary Artery Disease (CAD) Patients Aged 30 to 80 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to investigate the effect of nitroglycerin on vericiguat in patients
      with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat
      acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in
      the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important
      to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used
      as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as measure of safety and tolerability</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Regular measurement of blood pressure (mmHg) in supine, sitting and standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Regular measurement of heart rate (bpm) in supine, sitting and standing position.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Vericiguat + Nitroglycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of vericiguat and nitroglycerin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Nitroglycerin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aministration of matching placebo and nitroglycerin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vericiguat (BAY1021189)</intervention_name>
    <description>Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets</description>
    <arm_group_label>Vericiguat + Nitroglycerin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].</description>
    <arm_group_label>Placebo + Nitroglycerin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41</description>
    <arm_group_label>Vericiguat + Nitroglycerin</arm_group_label>
    <arm_group_label>Placebo + Nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with stable CAD defined by

          -  coronary artery stenosis in any of the 3 main coronary vessels &gt; 50% documented by
             coronary angiography within last 36 months or history of myocardial infarction

          -  Age: 30 to 80 years

          -  Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg / m²

          -  Female subjects must be of non-childbearing potential

        Exclusion Criteria:

          -  Intervention e.g. revascularization by percutaneous coronary intervention (PCI) and/or
             coronary artery bypass graft (CABG) during the last 3 months

          -  Progressive angina with symptoms of worsening of angina within the &lt; 3 months

          -  History of recent (&lt; 6 months prior to the first screening examination) myocardial
             infarction or unstable angina

          -  Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months
             prior or patients with stroke at more than 3 months prior with significant residual
             neurologic involvement

          -  Insulin dependent diabetes mellitus

          -  Clinically relevant cardiac ischemia

          -  Clinical significant persistent ischemia

          -  Atrial fibrillation, pacemaker, defibrillator, atrial ventricular (AV)-block II and
             III

          -  Systolic blood pressure below 110 or above 160 mmHg

          -  Diastolic blood pressure above 100 mmHg

          -  Heart rate below 50 or above 100 beats / min

          -  Estimated glomerular filtration rate &lt; 30 mL/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

